BibTex format
@article{Symes:2025:10.1016/S1473-3099(25)00546-8,
author = {Symes, R and Whitaker, HJ and Ahmad, S and Arnold, D and Banerjee, S and Evans, CM and Gore, R and Hart, J and Heaney, K and Kon, OM and Melhuish, A and Ortale, Zogaib M and Pelosi, E and Rahman, NM and Woltmann, G and McKeever, T and Zambon, M and Watson, CH and Lim, WS and Lopez, Bernal J and HARISS, network collaborators},
doi = {10.1016/S1473-3099(25)00546-8},
journal = {Lancet Infect Dis},
title = {Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75-79 years in England: a multicentre, test-negative, case-control study.},
url = {http://dx.doi.org/10.1016/S1473-3099(25)00546-8},
year = {2025}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BACKGROUND: A respiratory syncytial virus (RSV) vaccination programme for older adults using bivalent pre-F vaccine was introduced in England from Sept 1, 2024. Although vaccine effectiveness has been reported against all-cause RSV-associated respiratory hospital admissions, data are scarce on vaccine effectiveness against different presentations of RSV-associated illness, such as exacerbation of chronic illness. METHODS: This multicentre, test-negative, case-control study used data from a national, hospital-based, acute respiratory infection sentinel surveillance (HARISS) system across 14 hospitals in England. Eligibility criteria were vaccine-eligible adults aged 75-79 years admitted to hospital with acute respiratory infection (ARI) for ≥24 h and tested with molecular diagnostic assays within 48 h of admission. Cases were RSV positive, and controls were negative for RSV, influenza, and SARS-CoV-2. Vaccination status and data on sex were obtained from the National Immunisation Information System. The primary outcome was hospital admission due to RSV-associated ARI, which was tested for using nasopharyngeal or combined nose and throat swabs. Clinical data were collected using a structured questionnaire. FINDINGS: Between Oct 1, 2024, and March 31, 2025, 1006 older adults were admitted to hospital with ARI; 173 were RSV positive (cases) and 833 were RSV negative (controls). 526 (52·3%) of 1006 individuals were female and 480 (47·7%) were male. Mean age was 77·8 years (SD 1·4) in individuals who were RSV positive and 77·6 years (SD 1·3) in those who were negative for RSV, influenza, and SARS-CoV-2. Vaccine effectiveness was 82·3% (95% CI 70·6-90·0) against hospitalisation for any RSV-associated ARI and 86·7% (75·4-93·6) in those with severe disease including oxygen supplementation. Vaccine effectiveness was 88·6% (75·6-95·6) among individuals admitted due to lo
AU - Symes,R
AU - Whitaker,HJ
AU - Ahmad,S
AU - Arnold,D
AU - Banerjee,S
AU - Evans,CM
AU - Gore,R
AU - Hart,J
AU - Heaney,K
AU - Kon,OM
AU - Melhuish,A
AU - Ortale,Zogaib M
AU - Pelosi,E
AU - Rahman,NM
AU - Woltmann,G
AU - McKeever,T
AU - Zambon,M
AU - Watson,CH
AU - Lim,WS
AU - Lopez,Bernal J
AU - HARISS,network collaborators
DO - 10.1016/S1473-3099(25)00546-8
PY - 2025///
TI - Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75-79 years in England: a multicentre, test-negative, case-control study.
T2 - Lancet Infect Dis
UR - http://dx.doi.org/10.1016/S1473-3099(25)00546-8
UR - https://www.ncbi.nlm.nih.gov/pubmed/41167207
ER -
